#nktr | Explore Tumblr Posts and Blogs

hidamarirecord · 1 month

Text

can't sleep draw random self-fullfiling ocxcanon 1.5 panel stuff

#uma musume #nakayama festa #ocxcanon #nakatore #umamusume #female trainer #yuuhiocs:nncT #nktr #doodle comics

6 notes · View notes

tyrantorfevre · 2 months

Text

youtube

this song is the song i associate the most with female trainer and nakayama festa btw (turn on CC)

#sunset usamin rambles #god i love nktr..... they're such a spicy yuri #Youtube #nakatore

2 notes · View notes

nuovaalta2 · 2 months

Text

$NKTR #

The financial results will be released on Monday, March 4, 2024, after the close of U.S.-based financial markets. https://csimarket.com/stocks/at_glance.php?code=NKTR&utm_source=dlvr.it&utm_medium=tumblr

0 notes

jakedollars6 · 1 year

Photo

$NKTR 2.88 ...hodling to 6.25+ 👊 https://www.instagram.com/p/ClortPBpSY5/?igshid=NGJjMDIxMWI=

0 notes

petnews2day · 1 year

Text

Cyprus reports first human cases of bird flu

New Post has been published on https://petn.ws/nkTR

Cyprus reports first human cases of bird flu

Health officials in the Republic of Cyprus have confirmed two human cases of Avian influenza have been detected on the island for the first time, as bird flu sweeps through a number of countries. According to the Veterinary Services Department of the Agriculture Ministry, two cases of bird flu have been detected in two locations […]

See full article at https://petn.ws/nkTR #BirdNews

#Bird News

0 notes

reportstore · 2 years

Text

Riding Nektar’s wave: cytokine immunotherapies in oncology

Throughout the course of recent months, there has been tremendous attention on cytokines in oncology after Bristol-Myers Squibb (BMS) paid a dazzling $1.85B for rights to Nektar's lead investigational immuno-stimulatory asset, NKTR-214.

NKTR-214 is an engineered (pegylated) cytokine targeting the interleukin-2 (IL-2) receptor beta subunit, which can possibly turn "cold" tumors — tumors inadequately infiltrated with immune cells, and thus less responsive to immunotherapies — immunogenic. On account of this feature, IL-2-based therapies are touted as one of the most promising combinatorial methodologies with immune checkpoint barricade.

The sector is bustling with activity and various high-profile assets are in development. For instance, Immunservice's inhaled biomimetic IL-2 Pulmoleukin is in Phase II for lung metastases in renal cell carcinoma.

Likewise, Roche's RG7461, an IL-2 variant (IL-2v) linked to an anti-fibroblast activation protein (FAP) antibody, is in Phase II in combination with in-house modified death-ligand 1 (PD-L1) inhibitor Tecentriq (atezolizumab) for various solid tumors.

The biggest study is an ongoing pivotal trial testing Nektar's asset with BMS's Opdivo (nivolumab), a customized cell death protein-1 (PD-1) inhibitor, in 250 patients with various solid malignancies, as part of a collaboration wrote in 2016 between the two companies.

Although IL-2-based therapeutics are ahead with respect to clinical development, various other interleukin 1 receptor like 2 drugs development market projects in development are gaining traction, energized by the interest displayed in the sector following Nektar's prosperity.

Treading closely following IL-2 are IL-10 and IL-12, which have seen rekindled interest in oncology despite being previously tarnished by systemic toxicity, pharmacokinetic limitations, and an extremely thin therapeutic index.

A few different delivery mechanisms or plasmid vector technologies currently aim to address the limitations of these methodologies and have previously advanced into various oncology projects.

Armo Biosciences is in front of the load with pegilodecakin (AM0010), is a long-acting type of recombinant human IL-10. Attaching IL-10 to polyethylene glycol (PEG) drags out the presence of the particle in the circulation and within a tumor.

IL-10 stimulates the expansion and cytotoxic activity of CD8+ T-cells, which directly connect with and kill tumor cells. The readout of pegilodecakin's pivotal trial in pancreatic adenocarcinoma will be one of the main biotech events during this year's subsequent quarter.

#Interleukin 1 Receptor Like 2 Drugs Development Market

0 notes

stockcalc · 3 years

Text

Nektar Therapeutics (NKTR:NAS) Fundamental Valuation Report

Fundamental Valuation Report Nektar Therapeutics(NKTR:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$19.99 (USD) 03/26/2021 Weighted Valuation$24.92 (USD) Overall RatingUndervalued by 24.7% Valuation Models Comparables: $24.92 (USD) Valuation Methods This company is: Cash…

View On WordPress

0 notes

stockconsultant-blog · 5 years

Photo

$QURE (QURE) uniQure stock back to 59.68 double support area with bullish stats, also $CSBR $CUE $LPTX $NKTR $PULM $RARX bios, analysis https://stockconsultant.com/?QURE

#qure #csbr #cue #lptx #nktr #pulm #rarx #stocks #biotech #stockchart #biotechnology #stockmarket #stockpicks #stockstowatch

0 notes

hidamarirecord · 3 months

Text

"--Say. If I were to walk toward the ocean without stopping, would you let go of my hand?" ".....I would not let you go. Besides, you wouldn't do it, because your dream is finally at reach."

Nakayama Festa x fem!Trainer inspired by her Onsen ticket special scene.

#uma musume #nakayama festa #female trainer #umamusume #uma musume pretty derby #fanarts #hidamarirecord #i was looping yoru ni kakeru by yoasobi to get to the exact mood of this piece!!#overall im satisfied i'm able to draw this scene with my fem!trainer OC #ocxcanon #yuuhiocs: nncT #nktr

7 notes · View notes

chrstndvtt · 5 years

Text

Is there Trouble Brewing for for Nektar Therapeutics (NKTR)?

New Post has been published on https://www.instocknews.com/stocks-today/nktr/11467

Is there Trouble Brewing for for Nektar Therapeutics (NKTR)?

Let's look at NKTR stock. What do we think about Monday’s stock prices? Are we looking at a stock market crash? Possibly we will see stock price increases? On 14 January, Company stock for Nektar Therapeutics (NASDAQ:NKTR) saw trading gains. Stock increased 0.51 points, a 1.24 (%) change, now p...

#Earnings #NASDAQ #Rally #USD #Valuation #NKTR

0 notes

kreislercaregiverauthor · 5 years

Text

PainNewsNetwork ‘Opioid of the Future’ Postponed

By: Pat Anson, PNN Editor 7/26/19

The U.S. Food and Drug Administration is tapping the brakes on NKTR-181, an experimental opioid pain medication that has less abuse potential than traditional opioids like oxycodone or hydrocodone.

In an SEC filing, Nektar Therapeutics said it received a letter from the FDA on July 23 saying the agency was postponing all advisory…

View On WordPress

#60 Minutes #‘Opioid of the Future’#FDA #Howard Robin #iCare Consulting #[email protected]#iCareTalk.net #July 25 #NKTR-181 #PainNewsNetwork #Pat Anson #Postponed #Richard Kreis #SEC Filing #U.S. Food and Drug Administration

0 notes

lifewithchronicpain-original · 5 years

Text

The U.S. Food and Drug Administration is tapping the brakes on NKTR-181, a new type of opioid pain medication that that has less abuse potential than traditional opioids like oxycodone or hydrocodone.

In an SEC filing, Nektar Therapeutics said it had received a letter from the FDA on July 23 saying it was postponing all advisory committee meetings for opioid analgesics, including one scheduled for August 21, 2019 to discus Nektar’s new drug application for NKTR-181.

The FDA was due to make a final decision on the experimental drug eight days later, but that too may be postponed while the agency considers “a number of scientific and policy issues relating to this class of drugs.”

Nektar billed NKTR-181 as the “opioid of the future” because it is the first full mu-opioid agonist that can provide pain relief without the euphoria or “high” that can lead to abuse and addiction. The molecular structure of NKTR-181 is designed to have low permeability across the blood-brain barrier, which slows its rate of entry into the brain.

In a Phase III clinical study, patients with chronic back pain reported that their pain scores dropped by an average of 65% when taking NKTR-181 twice daily. Safety studies also found that recreational drug users had significantly less “drug liking” of NKTR-181 -- even at high doses -- when compared to oxycodone. (Read more at link)

#chronic pain #spoonies #opioid crisis #opioids #article #fda

66 notes · View notes

eightvape · 5 years

Link

Every SQN flavor is developed by a chef/sommelier and veteran vaper of over five years. Each flavor was developed with a delicate balance on the palate, complex flavors are presented in simplistic fashion, and each flavor offers a cleaner vaping experience with minimal carbon buildup on coils.

#NKTR #vape juice

0 notes

ustribunenews-blog · 6 years

Text

Analysts Forecast Upside for Nektar Therapeutics (Nasdaq:NKTR), Closing The Day At $39.89

Nektar Therapeutics (Nasdaq:NKTR)

October 22nd, 2018

Nektar Therapeutics finished Monday’s trading session down 17.22%, a $8.30 decrease to close on $39.89. Nektar Therapeutics bounced 24.11% between high and low. Despite the drop in value, trading volumes were solid at 312% of normal which can indicate investor opportunities. It’s expected that Nektar Therapeutics will report earnings within the…

View On WordPress

#Communication Services #Consumer Discretionary #Consumer Staples #Energy #finance #Financial Sector #Financials #Healthcare #Industrials #Information Technology #Materials #Nektar Therapeutics #news #NKTR #Real Estate #San Francisco #Utilities